Organogenesis says PREPARE RCT shows PuraPlyAM boosts 12-week closure rates in hard-to-heal diabetic foot ulcers

Bitget2026/10/12 20:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Organogenesis reported peer-reviewed publication of previously released PREPARE randomized trial results for PuraPlyAM in hard-to-heal diabetic foot ulcers.
Study met its primary endpoint, showing better wound closure outcomes at 12 weeks versus standard care alone.
Publication strengthens the clinical evidence base the company expects to support future payer coverage decisions for PuraPlyAM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121610PRIMZONEFULLFEED9844021) on October 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Organogenesis says PREPARE RCT shows PuraPlyAM boosts 12-week closure rates in hard-to-heal diabetic foot ulcers

You may also like

Crypto prices